

# L-165041

**Catalog No: tcsc0826**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

79558-09-1

**Formula:**

$C_{22}H_{26}O_7$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

PPAR

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

402.44

## Product Description


L-165041 is a cell permeable **PPAR $\delta$**  agonist, with **K<sub>i</sub>s** of 6 nM and appr 730 nM for PPAR $\delta$  and PPAR $\gamma$ , respectively, and induces

adipocyte differentiation in NIH-PPAR $\delta$  cells.

IC50 & Target: Ki: 6 nM (PPAR $\delta$ ), appr 730 nM (PPAR $\gamma$ )<sup>[1]</sup>

**In Vitro:** L-165041 is a PPAR $\delta$  agonist, with  $K_i$ s of 6 nM and appr 730 nM for PPAR $\delta$  and PPAR $\gamma$ , respectively<sup>[1]</sup>. L-165041 (1 or 5  $\mu$ M) inhibits VEGF-induced endothelial cells (ECs) proliferation and migration. L-165041 negatively affects cell cycle progression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041 (10  $\mu$ M) inhibits PPAR $\delta$ -independent, VEGF-induced angiogenesis<sup>[2]</sup>. PPAR $\delta$  ligand L-165041 inhibits PDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-induced cellular migration is inhibited. L-165041 (10  $\mu$ M) significantly suppresses S phase transition induced by PDGF<sup>[4]</sup>.

**In Vivo:** L-165041 (5 mg/kg/day, i.p.) significantly lowers the formation of lipid droplets in mice. L-165041 markedly reduces the level of both the hepatic cholesterol and triglycerides in mice. L-165041 increases mRNA expression levels of PPAR $\delta$  compared to the vehicle group. Lipoprotein lipase (LPL) expression in L-165041-treated mice is significantly higher than that in the vehicle group<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!